Alopecia areata
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
Alopecia areata e bonoa ka morao ho letlalo la hlooho. Maemong a tloaelehileng, e hlaha ka tšohanyetso ka holim'a metsi a boreleli ka ho feletseng le boholo ba 2-3 cm.
References
Alopecia areata ke boemo boo sesole sa hau sa 'mele se hlaselang li-follicle tsa moriri oa hau, se lebisang ho lahleheloa ke moriri ka nakoana ntle le maqeba. E ka bonahala e le maqeba a ho lahleheloa ke moriri kapa ea ama letlalo la hao kaofela kapa 'mele, e ama batho ba ka bang 2% ka nako e itseng bophelong ba bona. Molato o ka sehloohong o bonahala e le ho senyeha ha tšireletso ea tlhaho ho pota-potiloe ke moriri oa moriri.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata ke boemo boo sesole sa 'mele se hlaselang li-follicle tsa moriri, se bakang ho lahleheloa ke moriri holim'a hlooho le likarolo tse ling tse nang le moriri. E ama hoo e ka bang 2% ea batho lefatšeng ka bophara. Le hoja e ka etsahala lilemong life kapa life, e atile haholo baneng ho feta batho ba baholo (1. 92% vs. 1. 47%) . Basali, haholo-holo ba ka holimo ho lilemo tse 50, ba atisa ho e fumana ho feta banna. Ho kenya li-corticosteroids ka kotloloho libakeng tse amehileng ho bontšitse litholoana tse ntle ho feta ho li sebelisa ka holimo.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Ho lumeloa hore Alopecia areata ke lefu la autoimmune le amanang le sesole sa 'mele sa follicles ea moriri. Mochine o ka sehloohong o kenyelletsa ho hloleha ha 'mele ho lemoha lisele tsa oona, ka mor'a moo ho senyeha ha moriri oa moriri.
○ Kalafo - Lithethefatsi tsa OTC
Batho ba bang ba nang le alopecia areata e bobebe ba fola nakong ea selemo ntle le kalafo. Leha ho le joalo, batho ba bangata ba hlaheloa ke ho hlaha hape libakeng tse sa reroang hloohong.
#Hydrocortisone cream
○ Kalafo
Liente tsa Intralesional steroid ke phekolo e sebetsang ka ho fetisisa. Immunotherapy e ka lekoa haeba libaka tse kholo tsa letlalo la hlooho li ameha.
#Triamcinolone intralesional injection
#DPCP immunotherapy